

Reminder: ONLY SELECT Workers' Compensation Board – Alberta (Group 23737, Section A) worker claims are eligible for direct bill through Alberta Blue Cross®

We would like to remind pharmacies that only a select number of Workers' Compensation Board – Alberta (WCB-Alberta) worker claims are eligible for direct bill through the Alberta Blue Cross PrideRT system at this time. Additional worker claims will be added over the coming months, and workers with claims eligible for direct billing will receive a letter from WCB-Alberta notifying them of their eligibility. Workers who are eligible and would like to use this service are instructed to inform their pharmacy to direct bill their claim-related prescriptions.

If a worker's claim is not eligible for direct billing through Alberta Blue Cross PrideRT, pharmacies can still submit for remuneration from WCB-Alberta using Form C774 Pharmacy Prescription Invoice.

Additional information is available in the WCB-Alberta Pharmacy reference guide and frequently asked questions at ab.bluecross.ca/pdfs/reference-guide-and-faq-wcb-direct-bill.pdf and in Pharmacy Benefact 1087.

Updates to the Alberta Blue Cross Critical Supply List

The Alberta Blue Cross Critical Supply List has been updated to include temporary benefits added due to the shortage of products listed on the *Alberta Drug Benefit List (ADBL)*. Alberta Blue Cross continues to monitor drug product supply issues and update the Critical Supply List on an ongoing basis. The list can be found at ab.bluecross.ca/providers/pharmacy-resources.php.

Temporary Benefit added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of Lodalis 625 mg tablet (DIN 02373955) manufactured by Bausch Health, **Apo-Colesevelam 625 mg tablet (DIN 02494051)** manufactured by Apotex Inc. will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List **March 3, 2023**.

As of **March 3, 2023**, all claims for Apo-Colesevelam 625 mg tablet (DIN 02494051) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The ABCDPL is available online at ab.bluecross.ca/providers/pharmacy-home.php.

continued next page

continued from previous page

Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Teva Canada Limited that the shortage for Teva-Liothyronine 5 mcg tablet (DIN 02494337) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 6, 2023**. The following grouping was removed from the Critical Supply Product List **March 7, 2023**.

LIOTHYRONINE SODIUM

5 MCG TABLET

00002494337	TEVA-LIOTHYRONINE	TEV	\$ 1.1587
00001919458	CYTOMEL	PFI	\$ 1.4133

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Fluvoxamine 50 mg tablet (DIN 02231329) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 10, 2023**. The following grouping was removed from the Critical Supply Product List **March 8, 2023**.

FLUVOXAMINE MALEATE

50 MG TABLET

00002255529	ACT FLUVOXAMINE	APH	\$ 0.2105
00002231329	APO-FLUVOXAMINE	APX	\$ 0.2105
00001919342	LUVOX	BGP	\$ 1.0110

Alberta Blue Cross has been advised by Jamp Pharma Corporation and Sandoz Canada Inc. that the shortage for Jamp Pirfenidone 267 mg tablet (DIN 02514702) and Sandoz Pirfenidone 267 mg tablet (DIN 02488507) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 10, 2023**. The following grouping was removed from the Critical Supply Product List **March 10, 2023**.

PIRFENIDONE

267 MG TABLET

00002514702	JAMP PIRFENIDONE	JPC	\$ 6.7120
00002488507	SANDOZ PIRFENIDONE	SDZ	\$ 6.7120
00002464489	ESBRIET	HLR	\$ 13.4240

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

